FRET-based assay for intracellular evaluation of α-synuclein aggregation inhibitors

0548774 - ÚOCHB 2022 RIV US eng J - Článek v odborném periodiku
Galkin, Maksym - Priss, Anastasiia - Topcheva, O. - Yushchenko, Dmytro A. - Shvadchak, Volodymyr V.
FRET-based assay for intracellular evaluation of α-synuclein aggregation inhibitors.
Journal of Neurochemistry. Roč. 159, č. 5 (2021), s. 901-912. ISSN 0022-3042. E-ISSN 1471-4159
Grant CEP: GA ČR(CZ) GJ18-06255Y
Institucionální podpora: RVO:61388963
Klíčová slova: amyloid * assay * FRET * intracellular * Parkinson's Disease * α-synuclein
Obor OECD: Biophysics
Impakt faktor: 5.546, rok: 2021
Způsob publikování: Omezený přístup
https://doi.org/10.1111/jnc.15528

Aggregation of small neuronal protein α-synuclein (αSyn) in amyloid fibrils is considered to be one of the main causes of Parkinson's disease. Inhibition of this aggregation is a promising approach for disease treatment. Dozens of compounds able to inhibit αSyn fibrillization in solution were developed during the last decade. However, the applicability of most of them in the cellular environment was not established because of the absence of a suitable cell-based assay. In this work, we developed an assay for testing αSyn aggregation inhibitors in cells that is based on fluorescence resonance energy transfer (FRET) between labeled αSyn molecules in fibrils. The assay directly reports the amount of fibrillized αSyn and is more reliable than the assays based on cell viability. Moreover, we showed that cell viability decline does not always correlate with the amount of misfolded αSyn. The developed FRET-based assay does not interfere with the aggregation process and is suitable for high-throughput testing of αSyn aggregation inhibitors. Its application can sort out non-specific inhibitors and thus significantly facilitate the development of drugs for Parkinson`s disease.
Trvalý link: http://hdl.handle.net/11104/0324830